Neuropsychiatric symptoms (NPS) are prevalent in mild cognitive impairment (MCI), but we do not know much about their role in progression to dementia.
Objective:
To investigate NPS and the risk of progression to probable Alzheimer’s disease dementia (AD) among subjects with MCI.
Methods:
96 MCI participants were followed for 4 years. Progression to probable AD was defined by the change of CDR total score from 0.5 to ≥1, reviewed by an expert consensus panel. NPS were determined using the Neuropsychiatric Inventory (NPI) 12-items. This study analyzed prognostic value of each NPI item and 5 sub-syndromes of NPS (apathy, psychosis, affective, hyperactivity, and vegetative) for prediction of progression to probable AD. A Cox proportional hazard model was used; hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with time dependent variable to compare the incidence of progression considering presence/absence of any NPS or sub-syndromes throughout the study.
Results:
The presence of symptoms “agitation/aggression”, “delusions”, and “aberrant motor behavior” significantly increased the risk of probable AD (HR = 3.9; 95% CI = 1.9–8.2; HR = 13.9; 95% CI = 4.1–48.9; HR = 4.3; 95% CI = 1.7–10.3, respectively). The presence of sub-syndromes “psychosis” and “hyperactivity” were also predictors of progression (HR = 14.0; 95% CI = 4.4–44.5; HR = 2.0; 95% CI = 1.1–3.7, respectively). These results did not change after adjusting by potential confounders.
Conclusion:
Presence of delusions, agitation/aggression, and aberrant motor behavior is predictor of progression to probable AD.
RosenbergPB, MielkeMM, HanD, LeoutsakosJS, LyketsosCG, RabinsPV, ZandiPP, BreitnerJCS, NortonMC, Welsh-BohmerKA, ZuckermanIH, RattingerGB, GreenRC, CorcoranC, TschanzJT (2012) The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. Int J Geriatr Psychiatry27, 1248–1257.
2.
LyketsosCG, SteeleC, GalikE, RosenblattA, SteinbergM, WarrenA, SheppardJM (1999) Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry156, 66–71.
3.
KalesHC, ChenP, BlowFC, WelshDE, MellowAM (2005) Rates of clinical depression diagnosis, functional impairment, and nursing home placement in coexisting dementia and depression. Am J Geriatr Psychiatry13, 441–449.
4.
PetersME, SchwartzS, HanD, RabinsPV, SteinbergM, TschanzJT, LyketsosCG (2015) Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: The Cache County Dementia Progression Study. Am J Psychiatry172, 460–465.
LandauSM, HarveyD, MadisonCM, ReimanEM, FosterNL, AisenPS, PetersenRC, ShawLM, TrojanowskiJQ, JackCR, WeinerMW, JagustWJ, Alzheimer’s Disease Neuroimaging Initiative (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology75, 230–238.
7.
DickersonBC, SalatDH, GreveDN, ChuaEF, Rand-GiovannettiE, RentzDM, BertramL, MullinK, TanziRE, BlackerD, AlbertMS, SperlingRA (2005) Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology65, 404–411.
8.
OkelloA, KoivunenJ, EdisonP, ArcherHA, TurkheimerFE, NågrenK, BullockR, WalkerZ, KennedyA, FoxNC, RossorMN, RinneJO, BrooksDJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology73, 754–760.
9.
MattssonN, ZetterbergH, HanssonO, AndreasenN, ParnettiL, JonssonM, HerukkaS-K, van der FlierWM, BlankensteinMA, EwersM, RichK, KaiserE, VerbeekM, TsolakiM, MulugetaE, RosénE, AarslandD, VisserPJ, SchröderJ, MarcussonJ, de LeonM, HampelH, ScheltensP, PirttiläT, WallinA, JönhagenME, MinthonL, WinbladB, BlennowK (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385–393.
10.
PetersenRC, SmithGE, IvnikRJ, TangalosEG, SchaidDJ, ThibodeauSN, KokmenE, WaringSC, KurlandLT (1995) Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA273, 1274–1278.
11.
ForresterSN, GalloJJ, SmithGS, LeoutsakosJ-MS (2016) Patterns of neuropsychiatric symptoms in mild cognitive impairment and risk of dementia. Am J Geriatr Psychiatry24, 117–125.
12.
RosenbergPB, MielkeMM, ApplebyBS, OhES, GedaYE, LyketsosCG (2013) The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry21, 685–695.
13.
TengE, LuPH, CummingsJL (2007) Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer’s disease. Dement Geriatr Cogn Disord24, 253–259.
14.
PinkA, StokinGB, BartleyMM, RobertsRO, SochorO, MachuldaMM, Krell-RoeschJ, KnopmanDS, AcostaJI, ChristiansonTJ, PankratzVS, MielkeMM, PetersenRC, GedaYE (2015) Neuropsychiatric symptoms, APOE ɛ4, and the risk of incident dementia: A population-based study. Neurology84, 935–943.
15.
AaltenP, VerheyFRJ, BozikiM, BullockR, ByrneEJ, CamusV, CaputoM, CollinsD, De DeynPP, ElinaK, FrisoniG, GirtlerN, HolmesC, HurtC, MarriottA, MecocciP, NobiliF, OussetPJ, ReynishE, SalmonE, TsolakiM, VellasB, RobertPH (2007) Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: Part I. Dement Geriatr Cogn Disord24, 457–463.
16.
de MauléonA, SotoM, KiyasovaV, DelrieuJ, GuignotI, GaltierS, LilamandM, CantetC, LalaF, SastreN, AndrieuS, PueyoM, OussetPJ, VellasB (2017) The ROSAS Cohort: A prospective, longitudinal study of biomarkers for Alzheimer’s disease. Strategy, methods and initial results. J Prev Alzheimers Dis4, 183–193.
17.
Estévez-GonzálezA, KulisevskyJ, BoltesA, OtermínP, García-SánchezC (2003) Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer’s disease: Comparison with mild cognitive impairment and normal aging. Int J Geriatr Psychiatry18, 1021–1028.
18.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
19.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
20.
RosenWG, MohsRC, DavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141, 1356–1364.
21.
ReitanRM, WolfsonD (1994) A selective and critical review of neuropsychological deficits and the frontal lobes. Neuropsychol Rev4, 161–198.
22.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
23.
PedrosaH, De SaA, GuerreiroM, MarocoJ, SimoesMR, GalaskoD, de MendoncaA (2010) Functional evaluation distinguishes MCI patients from healthy elderly people–the ADCS/MCI/ADL scale. J Nutr Health Aging14, 703–709.
24.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314.
25.
CanevelliM, AdaliN, VoisinT, SotoME, BrunoG, CesariM, VellasB (2013) Behavioral and psychological subsyndromes in Alzheimer’s disease using the Neuropsychiatric Inventory. Int J Geriatr Psychiatry28, 795–803.
26.
AcostaI, BorgesG, Aguirre-HernandezR, SosaAL, PrinceM, 10/66 Dementia Research Group (2018) Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: A 10/66 Dementia Research Group study. Alzheimers Dement14, 271–279.
27.
ChanWC, LamLCW, TamCWC, LuiVWC, LeungGTY, LeeATC, ChanSSM, FungAWT, ChiuHFK, ChanWM (2011) Neuropsychiatric symptoms are associated with increased risks of progression to dementia: A 2-year prospective study of 321 Chinese older persons with mild cognitive impairment. Age Ageing40, 30–35.
28.
LeoutsakosJ-MS, ForresterSN, LyketsosCG, SmithGS (2015) Latent classes of neuropsychiatric symptoms in NACC Controls and conversion to mild cognitive impairment or dementia. J Alzheimers Dis48, 483–493.
29.
PalmerK, BergerAK, MonasteroR, WinbladB, BäckmanL, FratiglioniL (2007) Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology68, 1596–1602.
30.
RobertPH, BerrC, VolteauM, BertogliatiC, BenoitM, SarazinM, LegrainS, DuboisB, PréAL study (2006) Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: A one-year follow-up study. Clin Neurol Neurosurg108, 733–736.
31.
BrodatyH, HeffernanM, DraperB, ReppermundS, KochanNA, SlavinMJ, TrollorJN, SachdevPS (2012) Neuropsychiatric symptoms in older people with and without cognitive impairment. J Alzheimers Dis31, 411–420.
32.
MahL, BinnsMA, SteffensDC, Alzheimer’s Disease Neuroimaging Initiative (2015) Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry23, 466–476.
33.
PalmerK, Di IulioF, VarsiAE, GianniW, SancesarioG, CaltagironeC, SpallettaG (2010) Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer’s disease: The role of depression and apathy. J Alzheimers Dis20, 175–183.
34.
PocnetC, AntoniettiJ-P, DonatiA, PoppJ, RossierJ, von GuntenA (2015) Behavioral and psychological symptoms and cognitive decline in patients with amnestic MCI and mild AD: A two-year follow-up study. Int Psychogeriatr27, 1379–1389.
35.
HuX, MeiberthD, NewportB, JessenF (2015) Anatomical correlates of the neuropsychiatric symptoms in Alzheimer’s disease. Curr Alzheimer Res12, 266–277.
36.
BensamounD, GuignardR, FurstAJ, DerreumauxA, ManeraV, DarcourtJ, BenoitM, RobertPH, DavidR (2016) Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis49, 387–398.
37.
LehmannM, GhoshPM, MadisonC, LaforceR, Corbetta-RastelliC, WeinerMW, GreiciusMD, SeeleyWW, Gorno-TempiniML, RosenHJ, MillerBL, JagustWJ, RabinoviciGD (2013) Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease. Brain136, 844–858.
38.
Krell-RoeschJ, VassilakiM, MielkeMM, KremersWK, LoweVJ, VemuriP, MachuldaMM, ChristiansonTJ, SyrjanenJA, StokinGB, ButlerLM, TraberM, JackCR, KnopmanDS, RobertsRO, PetersenRC, GedaYE (2019) Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: The Mayo Clinic Study of Aging. Transl Psychiatry9, 123.
39.
ApostolovaLG, DiLJ, DuffyEL, BrookJ, ElashoffD, TsengC-H, FairbanksL, CummingsJL (2014) Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer’s disease. Dement Geriatr Cogn Disord37, 315–326.
40.
SugarmanMA, AloscoML, TripodisY, SteinbergEG, SternRA (2018) Neuropsychiatric symptoms and the diagnostic stability of mild cognitive impairment. J Alzheimers Dis62, 1841–1855.
41.
EdwardsER, SpiraAP, BarnesDE, YaffeK (2009) Neuropsychiatric symptoms in mild cognitive impairment: Differences by subtype and progression to dementia. Int J Geriatr Psychiatry24, 716–722.
42.
DavidND, LinF, PorsteinssonAP, Alzheimer’s Disease Neuroimaging Initiative (2016) Trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment. Am J Geriatr Psychiatry24, 70–80.
43.
IsmailZ, Agüera-OrtizL, BrodatyH, CieslakA, CummingsJ, FischerCE, GauthierS, GedaYE, HerrmannN, KanjiJ, LanctôtKL, MillerDS, MortbyME, OnyikeCU, RosenbergPB, SmithEE, SmithGS, SultzerDL, LyketsosC, NPS Professional Interest Area of the International Society of to Advance Alzheimer’s Research and Treatment (NPS-PIA of ISTAART) (2017) The Mild Behavioral Impairment Checklist (MBI-C): A rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis56, 929–938.
